In this episode of Inside GRAPPA, Dr. Joel Gelfand joins host Mio Nakamura to discuss a groundbreaking pragmatic trial that may transform access to phototherapy. A long-standing GRAPPA member and trailblazer in dermatologic research, Dr. Gelfand shares insights from the \"LITE Study,\" a patient-centered, nationwide trial comparing home-based vs. office-based phototherapy for psoriasis.
You'll hear:
• Why phototherapy remains a preferred treatment for many patients, even in the biologic era
• Surprising results comparing office phototherapy to adalimumab (a biologic) in previous trials
• How skin of color patients may benefit most from home phototherapy---and why
• Real-world barriers to accessing phototherapy and how the study tackled them head-on
• What's next: From research findings to implementation science and changing payer coverage
This episode is essential listening for dermatologists, rheumatologists, and researchers passionate about improving access and outcomes for patients with psoriatic disease. Tune in for a conversation that blends clinical science with patient advocacy---and may reshape the standard of care.
🧪 Learn more about PCORI's mission: pcori.org
📄 Stay tuned for the full publication of the LITE Study
💡 Want to get involved in pragmatic research? Dr. Gelfand shares how you can participate in studies like the CP3 trial—no research background required.
🎧 Subscribe to Inside GRAPPA for more deep dives into cutting-edge research on psoriatic disease.
","author_name":"GRAPPA Network"}